Liquid risperidone in the treatment of psychotic agitation (multiple letters)

CNS Drugs

Volumn 16, Issue 11, 2002, Pages 777-

  Tsai, Caroline ^a   Puzantian, Talia ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIPERIDONE; RISPERIDONE;

AGITATION; AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG INDICATION; HUMAN; LETTER; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0036032498     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216110-00006     Document Type: Letter

References (3)

1. 1. GW Currier A Trenton 2002 Pharmacological treatment of psychotic agitation CNS Drugs 16 4 219 28 11945106 10.2165/00023210-200216040-00002 1:CAS:528:DC%2BD38XktF2ks74%3D Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs 2002; 16(4): 219–28
2. 2. R Gutierrez PID Lee ML Huang 1997 Risperidone: effects of formulations on oral bioavailability Pharmacotherapy 17 3 599 605 9165565 1:CAS:528:DyaK2sXktFGlu7g%3D Gutierrez R, Lee PID, Huang ML, et al. Risperidone: effects of formulations on oral bioavailability. Pharmacotherapy 1997; 17(3): 599–605
3. 3. B Mehdi 2001 Pharmacokinetics: principles and applications McGraw-Hill Medical Publishing Division New York 247 66 Mehdi B. Pharmacokinetics: principles and applications. New York: McGraw-Hill Medical Publishing Division, 2001: 247–66